Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/26/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The warrants represent the right to purchase shares of Biofrontera Inc. stock under specific terms and conditions.
Core Business Areas
- Pharmaceuticals: Development and commercialization of prescription drugs for dermatology. They are focused on treating skin cancer and related diseases.
Leadership and Structure
The company is led by a CEO and has a structured management team overseeing research, development, and commercial operations. Specific names and org charts can be found in their public filings.
Top Products and Market Share
Key Offerings
- Ameluzu00ae: A topical prescription medicine used with photodynamic therapy (PDT) for the treatment of actinic keratoses (AK), a common pre-cancerous skin condition. Market share data varies by region and year. Competitors include other PDT treatments and topical creams such as imiquimod.
Market Dynamics
Industry Overview
The dermatology market is growing, driven by an aging population and increased awareness of skin cancer prevention and treatment.
Positioning
Biofrontera is positioned as a specialty pharmaceutical company focused on innovative dermatology products, particularly in the area of PDT.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the billions of dollars. Biofrontera's position depends on the penetration of their specific product, Ameluz, within the AK treatment market.
Upturn SWOT Analysis
Strengths
- Specialized focus on dermatology
- Approved prescription drug (Ameluzu00ae)
- Proprietary PDT technology
Weaknesses
- Reliance on a single product (Ameluzu00ae)
- Competition from established pharmaceutical companies
- Potential regulatory hurdles
Opportunities
- Expansion into new markets
- Development of new dermatology products
- Partnerships and collaborations
Threats
- Generic competition
- Changes in reimbursement policies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LEO Pharma
- Galderma
- Sun Pharmaceutical Industries
Competitive Landscape
Biofrontera competes in a market with established pharmaceutical companies. Their advantage lies in their specialized focus and proprietary technology. Their disadvantage includes resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to the success of Ameluzu00ae sales and market penetration.
Future Projections: Future growth depends on factors such as market expansion, new product development, and regulatory approvals. Analyst estimates available from financial analysis websites.
Recent Initiatives: Monitor their press releases for recent strategic initiatives.
Summary
Biofrontera Inc. is a small cap biopharmaceutical company focused on dermatology, primarily known for Ameluzu00ae. Its strength lies in its specialized focus, but faces risks like reliance on a single product and intense competition. Future growth depends on successful market expansion and new product development, requiring careful management of resources and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Biofrontera Inc. Financial Reports
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.